Volcano Corp (NASDAQ:VOLC)
The Company is engages in the development, manufacture and commercialization of intravascular ultrasound and functional measurement products that are used for the diagnosis and treatment of vascular and structural heart disease.
- Quote
- Commentary
- Scorecard
- Historical Prices
- Chart
- Stats
- Ratios
- Earnings/Growth Rates
- Statements
- SEC Filings
Recs
VOLC positively shouts "Short" (which I see already applies to nearly 10% of its float). Every place I looked, the numbers looked bad: declining earnings, astronomical PE, negative free-cash flow, etc. On top of that, it's a medical device company with no doctors among top officers; and it's quite a young company with relatively low management ownership and a very high institutional ownership share. Taken altogether, it looks like about $6/sh. might currently be a reasonable price, and if it has a couple really lousy quarters in a row and the institutional investors start tiptoeing out of it, that's probably about where the price will settle.
Recs
This is a company with unique technology in a growing market. They are preparing for expansion and will easily outperform the market for the next 2-3 years.
Recs
Price to Earnings (P/E) ? 152 VERY HIGH
and new 52 week high in a soon to be bear market
sell high buy low
Recs
Good growth and earnings.
Recs
Healthcare sector to unstable to call due to new laws in the works
Recs
Great pipeline of products.
Recs
volcano's IVUS system rocks... or so I've heard.
Recs
Growing leader in a growing market. You do the math.
Recs
Has a great line of products , and as the population ages more of its products will be in demand. I see this company growing steadily , and or being bought out - either way I'm going to make money .
Recs
covered some shares on 9-20
Recs
technology wins in the end. they built a better mousetrap.
Recs
this company has some good products, and the price had beaten down so much.
Recs
with all the baby boomers, how can it be wrong to pick stocks in health care? thats right it can't.
Recs
35% yoy rev increase!
Recs
This co is working on some new products which will address ovesity, one of our major medical problems in the US--and the world.
Recs
Technology seems sound and likelihood above average that it will become used fairly widely. Buyout by Medtronic, GE or other large medical imaging or ultrasound company seems possible.
Recs
product is best in show probably a buyout canidate
Recs
almost finished forming a double bottom...
Recs
IVUS...enough said............
Recs
Volcano helps to get the blood flowing in the human heart. The company makes a variety of medical devices that diagnose and treat heart disease, including atherosclerosis. Its intravascular ultrasound (IVUS) devices give information about the condition of arteries as well as plaque and lesions. Its functional measurement (FM) products measure characteristics of blood around plaque in arteries. The company sells its products to physicians and other health care providers worldwide through a direct sales force.
During August 2006 Volcano and GE Healthcare announced the US FDA (FDA) 510(k) clearance for the integration of Volcano's IVUS capabilities onto the Innova all-digital X-ray cath-lab imaging system. This digital imaging system is designed to give interventional cardiologists and interventional radiologists a clearer view of coronary and peripheral vessel morphology in a more accessible manner than previously available.
During the last quarter of 2006, Volcano announced collaboration with three leading core labs under which the company will provide IVUS catheters free of charge for use in pivotal trials for drug-eluting stents to facilitate the use of IVUS and demonstrate its value in stent optimization. The company is in the final trial design for the CHECK study, or Carotid Histology Evaluation and Correlation to patient worKup that will be a registry of stented carotid artery patients worldwide who undergo IVUS imaging.
Currently, more than 2,500 IVUS and FM systems are installed worldwide, with approximately half of its revenues coming from outside the US. For all of fiscal 2006, Volcano reported revenues of $103.0 million, a 12% rise over revenues of $91.9 million in fiscal 2005, thanks to the IVUS disposable revenues that increased nearly 25 percent. Volcano’s management expects revenues of approximately $120.0 million in fiscal 2007, nearly a 17% increase. In view of a stable business model, strong product line, worldwide sales stretch and recent collaborations, Volcano appears as a compelling investment idea.
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 20 of 29 : 1 2 Next »